SCHEMBL14133409

SCHEMBL14133409

O=C1NC(=S)S/C1=C\c1cn(-c2ccccc2)nc1-c1ccc(S(=O)(=O)N2CCOCC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUSP3 P51452 2/20 0.67
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
LMNA P02545 1/20 0.60
POLB P06746 1/20 0.60
MAPT P10636 1/20 0.60
HPGD P15428 1/20 0.60
MAPK1 P28482 1/20 0.60
HTT P42858 1/20 0.60
MCL1 Q07820 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
SAE1 Q9UBE0 1/20 0.60
UBA2 Q9UBT2 1/20 0.60
PTPRC P08575 1/20 0.56
PTPN1 P18031 1/20 0.56
DUSP1 P28562 1/20 0.56
PTPN7 P35236 1/20 0.56
PTP4A3 O75365 1/20 0.53
DUSP4 Q13115 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7852515 0.85 DUSP3 (0.77) DUSP3MEN1KMT2APOLBMAPT
SCHEMBL8374542 0.83 DUSP3 (0.81) DUSP3MEN1KMT2APOLBMAPT
SCHEMBL14133414 0.81 DUSP3 (0.78) DUSP3MEN1KMT2APOLBMAPT
SCHEMBL14133570 0.81 MAPT (0.66) DUSP3MEN1KMT2ALMNAPOLB
SCHEMBL1902207 0.81 DUSP3 (1.00) DUSP3MEN1KMT2APOLBMAPT
SCHEMBL1902206 0.81 DUSP3 (1.00) DUSP3MEN1KMT2APOLBMAPT
SCHEMBL1902208 0.81 DUSP3 (1.00) DUSP3MEN1KMT2APOLBMAPT
SCHEMBL12328694 0.80 DUSP3 (0.57) DUSP3MEN1KMT2ALMNAPOLB
SCHEMBL12297554 0.77 DUSP3 (0.57) DUSP3MEN1KMT2ALMNAPOLB
SCHEMBL7862709 0.76 PTPN1 (0.76) DUSP3MEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302581-A1 Methods and Compositions for the Treatment of RAS Associated Disorders THE TRUSTEES OF DARTMOUTH COLLEGE 2012-11-29 US disclosed
US-20120302581-A1 Methods and Compositions for the Treatment of RAS Associated Disorders THE TRUSTEES OF DARTMOUTH COLLEGE 2012-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302581-A1 Methods and Compositions for the Treatment of RAS Associated Disorders NRAS, HRAS, KRAS DUSP3 275/4885MEN1 40/4885KMT2A 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.